Inactive Instrument

AB-BIOTICS SA Stock BME

Biotechnology & Medical Research

AB-Biotics SA, also known as AB Biotics, is a Spain-based company engaged in the biotechnology industry business sector. It is dedicated to the research and development (R&D) of functional ingredients, drugs and tools for genetic analysis, as well as the nutraceutical and pharmaceutical industries. The Companyâ€™s pipeline includes a range of supplements designed to improve health, from products that can lower the risk of cardiovascular disease to those that can help in the management of diabetes. It covers the development spectrum from marketed product, to proof-of-concept, and includes products that have been licensed to global food and pharmaceutical companies. The Company also provides outsourced R&D solutions to pharmaceutical companies, as well as functional food industry related companies. The Company offers different products, such as AB-Life, LipiGO, AB-Dentalac and AB-Colic, among others.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	62.54M 53.81M 50.5M 46.2M 86.24M 5.91B 86.92M 597M 233M 3.02B 235M 230M 9.73B	P/E 2017	-21.2x	P/E 2018	31.7x
Enterprise Value	60.11M 51.72M 48.53M 44.4M 82.87M 5.68B 83.53M 574M 224M 2.9B 226M 221M 9.35B	EV / Sales 2017	2.22x	EV / Sales 2018	2.88x
Free-Float	31.56%	Yield 2017 *	-	Yield 2018	-

01/06/22	AB-Biotics, S.A. acquired Alifarm S.A. for EUR 3.5 million.	CI
07/11/19	Kaneka Europe Holding Company N.V. completed the acquisition of 18.21% stake in AB-Biotics, S.A.	CI
03/09/19	Kaneka Europe Holding Company N.V. made an offer to acquire remaining 33.67% stake in AB-Biotics, S.A. for €21.2 million.	CI
16/08/19	Kaneka Corporation has completed the voluntary offer to acquire an additional 26.57% stake in AB-Biotics, S.A. for €16.7 million.	CI
10/07/19	Kaneka Corporation made a voluntary public offer to acquire the remaining 60.24% stake in AB-Biotics, S.A. for €37.9 million.	CI
22/03/19	Ab-Biotics Sa Reports Earnings Results for the Full Year Ended December 31, 2018	CI
11/05/18	Kaneka Corporation Concludes License Agreement with AB-Biotics for Production and Sales of its Probiotics Products	CI
05/04/18	Kaneka Corporation completed the acquisition of 26.87% stake in AB-Biotics, S.A. from Corporacion Ivamosa, Gestion Y Administracion Mobiliaria, S.A., Capital MAB, FCR fund of Institut Català de Finances Capital, SGEIC, S.A. and Buanaventura Guamis.	CI
03/04/18	Kaneka Americas Holding Inc. enters into Licensing Agreement with AB-Biotics, S.A	CI
28/03/18	Kaneka Corporation signed an agreement to acquire 26.87% stake in AB-Biotics, S.A. from Corporacion Ivamosa, Gestion Y Administracion Mobiliaria, S.A., Capital MAB, FCR fund of Institut Català de Finances Capital, SGEIC, S.A. and Buanaventura Guamis.	CI
16/03/18	Corporacion Ivamosa and Gestion Y Administracion Mobiliaria, S.A. acquired 10% stake in AB-Biotics, S.A..	CI
08/11/17	Frutarom Industries Ltd. acquired AB-Fortis from AB-Biotics, S.A..	CI
25/10/16	AB-Biotics SA announced a financing transaction	CI

Director	Title	Age	Since
Sergi Audivert Brugué CHM	Chairman	-	-
Miquel Àngel Bonachera Sierra BRD	Director/Board Member	-	23/04/2004
Kazuhiko Fujii BRD	Director/Board Member	65	02/07/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB-BIOTICS SA	-.--%	-.--%	-	-	69.57M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-0.36%	-7.07%	+91.21%	+260.79%	3.94B
IOVANCE BIOTHERAPEUTICS, INC.	+0.93%	+5.33%	+293.67%	+41.46%	3.9B
VERACYTE, INC.	-0.47%	-1.28%	+45.89%	+67.30%	3.61B
CAREDX, INC.	+0.52%	-4.77%	+291.67%	+412.44%	2.57B
BGI GENOMICS CO., LTD.	-0.85%	-8.00%	-27.87%	-30.30%	2.16B
MARAVAI LIFESCIENCES HOLDINGS, INC.	-0.14%	-11.95%	+212.29%	-28.45%	1.1B
SEEGENE, INC.	-1.71%	-2.02%	+23.24%	+42.76%	1.08B
CURIOX BIOSYSTEMS CO., LTD	-1.93%	-11.52%	+14.96%	+58.95%	625M
HANGZHOU ALLTEST BIOTECH CO., LTD.	-1.13%	-5.18%	-34.79%	-5.83%	531M
Average	-0.51%	-5.27%	+101.14%	+91.01%	2.17B
Weighted average by Cap.	-0.19%	-2.81%	+133.75%	+126.76%

	2017	2018
Net sales	7.72M 6.64M 6.23M 5.7M 10.64M 730M 10.73M 73.73M 28.71M 373M 28.99M 28.36M 1.2B	12.59M 10.84M 10.17M 9.3M 17.36M 1.19B 17.5M 120M 46.84M 608M 47.29M 46.26M 1.96B
Net income	-895K -770K -722K -661K -1.23M -84.58M -1.24M -8.55M -3.33M -43.23M -3.36M -3.29M -139M	1.22M 1.05M 984K 900K 1.68M 115M 1.69M 11.64M 4.53M 58.85M 4.57M 4.47M 190M
Net Debt	-1.86M -1.6M -1.5M -1.37M -2.56M -176M -2.58M -17.75M -6.91M -89.75M -6.98M -6.82M -289M	-2.44M -2.1M -1.97M -1.8M -3.36M -231M -3.39M -23.29M -9.07M -118M -9.16M -8.96M -379M

AB-BIOTICS SA Stock BME

Stocks

Biotechnology & Medical Research

Valuation : AB-BIOTICS SA

Latest news : AB-BIOTICS SA

Managers and Directors : AB-BIOTICS SA

Bio Diagnostics & Testing

Financials

Company Profile